These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

822 related articles for article (PubMed ID: 23158822)

  • 1. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
    Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
    Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
    Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
    Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
    Garcia-Carrasco M; Mendoza-Pinto C; Sandoval-Cruz M; Soto-Vega E; Beltran-Castillo A; Jimenez-Hernandez M; Graillet D; Gonzalez L; Rojas-Rodriguez J; Pineda-Almazana A; Zamudio-Huerta L; Lopez-Colombo A
    Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
    Jovancevic B; Lindholm C; Pullerits R
    Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece.
    Trachana M; Koutsonikoli A; Farmaki E; Printza N; Tzimouli V; Papachristou F
    Rheumatol Int; 2013 Mar; 33(3):809-13. PubMed ID: 22101555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE.
    Watson L; Beresford MW; Maynes C; Pilkington C; Marks SD; Glackin Y; Tullus K
    Lupus; 2015 Jan; 24(1):10-7. PubMed ID: 25117653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR; Gordon C
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab therapy for childhood-onset systemic lupus erythematosus.
    Willems M; Haddad E; Niaudet P; Koné-Paut I; Bensman A; Cochat P; Deschênes G; Fakhouri F; Leblanc T; Llanas B; Loirat C; Pillet P; Ranchin B; Salomon R; Ulinski T; Bader-Meunier B;
    J Pediatr; 2006 May; 148(5):623-627. PubMed ID: 16737873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy.
    Tsai MJ; Chou CW; Lin FC; Chang SC
    Lupus; 2012 Jul; 21(8):914-8. PubMed ID: 22287506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus.
    Galarza-Maldonado C; Kourilovitch MR; Molineros JE; Cardiel MH; Zurita L; Soroka NF; Yagur VY; Doukh N; Cervera R
    Autoimmun Rev; 2010 Dec; 10(2):108-11. PubMed ID: 20804861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rituximab in pediatric patients with systemic lupus erythematosus].
    Pavón-Sánchez JM; Sánchez-Sánchez LM
    Gac Med Mex; 2013; 149(5):492-6. PubMed ID: 24108334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone.
    Gonzalez-Echavarri C; Pernas B; Ugarte A; Ruiz-Irastorza G
    Lupus; 2014 Mar; 23(3):323-6. PubMed ID: 24531426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term follow-up of patients with refractory systemic lupus erythematosus during rituximab treatment].
    Tsanian MÉ; Solov'ev SK; Torgashina AV; Aleksandrova EN; Radenska-Lopovok SG; Nikolaeva EV; Khrennikova IaB; Nasonov EL
    Ter Arkh; 2014; 86(5):40-9. PubMed ID: 25026801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current role of rituximab in systemic lupus erythematosus.
    Mok CC
    Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study.
    Fernández-Nebro A; de la Fuente JL; Carreño L; Izquierdo MG; Tomero E; Rúa-Figueroa I; Hernández-Cruz BE; Narváez J; Ucar E; Olivé A; Zea A; Fernández-Castro M; Raya-Álvarez E; Pego-Reigosa JM; Freire M; Martínez-Taboada VM; Pérez-Venegas J; Sánchez-Atrio AI; Villa-Blanco I; Manrique-Arija S; López-Longo FJ; Carreira PE; Martínez-Pérez R; García-Vicuña R
    Lupus; 2012 Sep; 21(10):1063-76. PubMed ID: 22786985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry.
    Iaccarino L; Bartoloni E; Carli L; Ceccarelli F; Conti F; De Vita S; Ferraccioli G; Galeazzi M; Gatto M; Gerli R; Govoni M; Gremese E; Iuliano A; Mansutti E; Moroni G; Mosca M; Nalli C; Naretto C; Padovan M; Palma L; Raffiotta F; Roccatello D; Tincani A; Valesini G; Zen M; Doria A
    Clin Exp Rheumatol; 2015; 33(4):449-56. PubMed ID: 26053285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.
    Davies RJ; Sangle SR; Jordan NP; Aslam L; Lewis MJ; Wedgwood R; D'Cruz DP
    Lupus; 2013 May; 22(6):574-82. PubMed ID: 23632989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
    Kumar S; Benseler SM; Kirby-Allen M; Silverman ED
    Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen.
    Ezeonyeji AN; Isenberg DA
    Rheumatology (Oxford); 2012 Mar; 51(3):476-81. PubMed ID: 22096015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.